141 related articles for article (PubMed ID: 7643525)
1. Zaprinast accelerates recovery from established acute renal failure in the rat.
Guan Z; Miller SB; Greenwald JE
Kidney Int; 1995 Jun; 47(6):1569-75. PubMed ID: 7643525
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cGMP-phosphodiesterase restores the glomerular effects of atrial natriuretic factor in low sodium diet rats.
Kalinowski L; Szczepanska-Konkel M; Pawelczyk T; Bizon D; Angielski S
Ren Physiol Biochem; 1995; 18(5):254-66. PubMed ID: 8869083
[TBL] [Abstract][Full Text] [Related]
3. Effects of zaprinast on renal nerve stimulation-induced anti-natriuresis in anaesthetized dogs.
Sekizawa T; Shima Y; Yoshida K; Tanahashi M; Yoshida M; Suzuki-Kusaba M; Hisa H; Satoh S
Clin Exp Pharmacol Physiol; 1998 Dec; 25(12):1008-12. PubMed ID: 9887998
[TBL] [Abstract][Full Text] [Related]
4. Studies on potential involvement of protein kinase C in glomerular insensitivity to atrial natriuretic factor on low sodium intake.
Kalinowski L; Szczepańska-Konkel M; Jankowski M; Angielski S
Med Sci Monit; 2001; 7(4):628-34. PubMed ID: 11433187
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide synthase and cGMP-mediated stimulation of renin secretion.
Sayago CM; Beierwaltes WH
Am J Physiol Regul Integr Comp Physiol; 2001 Oct; 281(4):R1146-51. PubMed ID: 11557622
[TBL] [Abstract][Full Text] [Related]
6. Urodilatin, not nitroprusside, combined with dopamine reverses ischemic acute renal failure.
Shaw S; Weidmann P; Zimmermann A
Kidney Int; 1992 Nov; 42(5):1153-9. PubMed ID: 1453600
[TBL] [Abstract][Full Text] [Related]
7. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation.
Ni XP; Safai M; Gardner DG; Humphreys MH
Kidney Int; 2001 Apr; 59(4):1264-73. PubMed ID: 11260387
[TBL] [Abstract][Full Text] [Related]
8. Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites.
Angeli P; Jiménez W; Veggian R; Fasolato S; Volpin R; MacHenzie HS; Craighero R; Libera VD; Sticca A; Arroyo V; Gatta A
Hepatology; 2000 Feb; 31(2):304-10. PubMed ID: 10655250
[TBL] [Abstract][Full Text] [Related]
9. Cyclic GMP-phosphodiesterase inhibition does not alter cerebral oxygen consumption.
Wei HM; Shah AJ; Tse J; Chi OZ; Weiss HR
Neurochem Res; 1996 Jan; 21(1):41-6. PubMed ID: 8833222
[TBL] [Abstract][Full Text] [Related]
10. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts.
Weiss HR; Rodriguez E; Tse J; Scholz PM
Clin Exp Pharmacol Physiol; 1994 Aug; 21(8):607-14. PubMed ID: 7813120
[TBL] [Abstract][Full Text] [Related]
11. N omega-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast.
Dundore RL; Pratt PF; O'Connor B; Buchholz RA; Pagani ED
Eur J Pharmacol; 1991 Jul; 200(1):83-7. PubMed ID: 1663042
[TBL] [Abstract][Full Text] [Related]
12. Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natriuretic factor.
Weishaar RE; Kobylarz-Singer DC; Keiser J; Haleen SJ; Major TC; Rapundalo S; Peterson JT; Panek R
Hypertension; 1990 May; 15(5):528-40. PubMed ID: 2158939
[TBL] [Abstract][Full Text] [Related]
13. Atrial natriuretic factor activates cyclic adenosine 3',5'-monophosphate phosphodiesterase in Xenopus laevis oocytes and potentiates progesterone-induced maturation via cyclic guanosine 5'-monophosphate accumulation.
Sandberg K; Bor M; Ji H; Carvallo PM; Catt KJ
Biol Reprod; 1993 Nov; 49(5):1074-82. PubMed ID: 8286573
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
Harris AL; Lemp BM; Bentley RG; Perrone MH; Hamel LT; Silver PJ
J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Merkel LA; Rivera LM; Perrone MH; Lappe RW
Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
[TBL] [Abstract][Full Text] [Related]
16. Lack of effect of zaprinast on methacholine-induced contraction and inositol 1,4,5-trisphosphate accumulation in bovine tracheal smooth muscle.
Chilvers ER; Giembycz MA; Challiss RA; Barnes BJ; Nahorski SR
Br J Pharmacol; 1991 May; 103(1):1119-25. PubMed ID: 1652339
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.
Trapani AJ; Smits GJ; McGraw DE; McMahon EG; Blaine EH
J Pharmacol Exp Ther; 1991 Jul; 258(1):269-74. PubMed ID: 1649294
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibitor, zaprinast, selectively increases cerebral blood flow in the ischemic penumbra in the rat brain.
Gao F; Sugita M; Nukui H
Neurol Res; 2005 Sep; 27(6):638-43. PubMed ID: 16157016
[TBL] [Abstract][Full Text] [Related]
19. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
20. Modulation of rabbit ventricular cell volume and Na+/K+/2Cl- cotransport by cGMP and atrial natriuretic factor.
Clemo HF; Feher JJ; Baumgarten CM
J Gen Physiol; 1992 Jul; 100(1):89-114. PubMed ID: 1355106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
